Mga Batayang Estadistika
| LEI | 549300T23BL59LCOH584 |
| CIK | 1581280 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Twist Bioscience Corporation
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 6, 2025 |
Twist Bioscience Appoints Trynka Shineman Blake to Board of Directors Twist Bioscience Appoints Trynka Shineman Blake to Board of Directors SOUTH SAN FRANCISCO, Calif. |
|
| August 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 5, 2025 Twist Bioscience Corporation (Exact name of registrant as specified in its charter) Delaware 001-38720 46-2058888 (State or other jurisdiction of incorporation) (Commiss |
|
| August 4, 2025 |
Exhibit 10.2 Certain information in this document identified by brackets [***] has been omitted because it is both (i) not material and (ii) the type that Twist Bioscience Corporation customarily and actually treats as private and confidential. LICENSE AGREEMENT THIS LICENSE AGREEMENT (the “Agreement”), dated as of May 2, 2025, is entered into by and between Twist Bioscience Corporation, a Delawar |
|
| August 4, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 00 |
|
| August 4, 2025 |
Exhibit 99.1 Twist Bioscience Reports Fiscal Third Quarter 2025 Financial Results — Record revenue of $96.1 million in 3QFY25; Increase of 18% over $81.5 million in 3QFY24, 10th consecutive quarter of sequential growth — — Gross margin of 53.4% in 3QFY25 versus 43.3% in 3QFY24; Improvement of 10.1 margin percentage points — — Expect revenue in the range of $374.0 million to $376.0 million for full |
|
| August 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 4, 2025 Twist Bioscience Corporation (Exact name of registrant as specified in its charter) Delaware 001-38720 46-2058888 (State or other jurisdiction of incorporation) (Commiss |
|
| August 4, 2025 |
Exhibit 10.3 Certain information in this document identified by brackets [***] has been omitted because it is both (i) not material and (ii) the type that Twist Bioscience Corporation customarily and actually treats as private and confidential. MES SOFTWARE LICENSE AGREEMENT THIS MES SOFTWARE LICENSE AGREEMENT (the “Agreement”), dated as of May 2, 2025, is entered into by and between Twist Bioscie |
|
| August 4, 2025 |
Exhibit 10.1 Certain information in this document identified by brackets [***] has been omitted because it is both (i) not material and (ii) the type that Twist Bioscience Corporation customarily and actually treats as private and confidential. CONTRIBUTION AGREEMENT BY AND BETWEEN TWIST BIOSCIENCE CORPORATION AND ATLAS DATA STORAGE, INC. May 2, 2025 TABLE OF CONTENTS Page Section 1.1 Definitions |
|
| May 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0 |
|
| May 5, 2025 |
Exhibit 99.2 Twist Bioscience Spins Out DNA Data Storage as Independent Company Spin out expected to unlock value by accelerating data storage technology development and allowing each company to focus strategically on its unique products, customers and investors Atlas Data Storage, a newly formed company, will focus solely on DNA data storage technology and commercialization, with $155 million in |
|
| May 5, 2025 |
Exhibit 99.1 Twist Bioscience Reports Fiscal Second Quarter 2025 Financial Results — Record revenue of $92.8M in 2QFY25; Increase of 23% over $75.3M in 2QFY24, 9th consecutive quarter of sequential growth — — Gross margin of 49.6% in 2QFY25 versus 41.0% in 2QFY24; Improvement of 8.6 margin percentage points — — Expect revenue in the range of $372 million to $379 million for full year fiscal 2025; |
|
| May 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 2, 2025 Twist Bioscience Corporation (Exact name of registrant as specified in its charter) Delaware 001-38720 46-2058888 (State or other jurisdiction of incorporation) (Commission |
|
| February 12, 2025 |
Amended and Restated Inducement Equity Incentive Plan and forms of agreements thereunder. Exhibit 99.2 TWIST BIOSCIENCE CORPORATION AMENDED AND RESTATED INDUCEMENT EQUITY INCENTIVE PLAN 1. Purposes of the Plan. The purposes of this Plan are to attract the best available personnel to ensure the Company’s success and accomplish the Company’s goals by providing a material inducement to individuals entering or re-entering into employment with the company or any Parent or Subsidiary of the |
|
| February 12, 2025 |
Calculation of Filing Fee Tables S-8 Twist Bioscience Corp Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Common Stock, $0. |
|
| February 12, 2025 |
As filed with the Securities and Exchange Commission on February 12, 2025 As filed with the Securities and Exchange Commission on February 12, 2025 Registration No. |
|
| February 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 5, 2025 Twist Bioscience Corporation (Exact name of registrant as specified in its charter) Delaware 001-38720 46-2058888 (State or other jurisdiction of incorporation) (Commi |
|
| February 11, 2025 |
Certificate of Amendment to Amended and Restated Certificate of Incorporation Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE Amended and Restated Certificate of Incorporation OF TWIST BIOSCIENCE CORPORATION The undersigned, Emily Leproust, hereby certifies that: 1. She is the duly elected and acting Chief Executive Officer of Twist Bioscience Corporation, a Delaware corporation (the “Corporation”). 2. The name of the Corporation is Twist Bioscience Corpor |
|
| February 11, 2025 |
Amended and Restated 2018 Equity Incentive Plan and forms of agreements thereunder Exhibit 10.2 TWIST BIOSCIENCE CORPORATION 2018 EQUITY INCENTIVE PLAN Amended and Restated Effective as of February 5, 2025 1. Purposes of the Plan. The purposes of this Plan are (a) to attract and retain the best available personnel to ensure the Company’s success and accomplish the Company’s goals; (b) to incentivize Employees, Directors and Independent Contractors with long-term equi |
|
| February 3, 2025 |
Exhibit 99.1 Twist Bioscience Reports Fiscal First Quarter 2025 Financial Results — Record revenue of $88.7M in 1QFY25; Increase of 24% over $71.5M in 1QFY24, 8th consecutive quarter of sequential growth — — Gross margin of 48.3% in 1QFY25; Improvement of 7.8 margin points versus 40.5% in 1QFY24 — — Expect revenue in the range of $372 million to $379 million for full year fiscal 2025; expect gross |
|
| February 3, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number |
|
| February 3, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 3, 2025 Twist Bioscience Corporation (Exact name of registrant as specified in its charter) Delaware 001-38720 46-2058888 (State or other jurisdiction of incorporation) (Commi |
|
| January 6, 2025 |
TABLE OF CONTENTS SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy Statement o Definitive Additional Materials o Soliciting Material Pursuant to § 240. |
|
| December 26, 2024 |
TWIST BIOSCIENCE CORPORATION AMENDED AND RESTATED 2018 EQUITY INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD AGREEMENT Unless otherwise defined herein, the terms defined in the Twist Bioscience Corporation Amended and Restated 2018 Equity Incentive Plan (the “Plan”) will have the same defined meanings in this Restricted Stock Unit Award Agreement (the “Award Agreement”). |
|
| December 26, 2024 |
TABLE OF CONTENTS SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: x Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Definitive Proxy Statement o Definitive Additional Materials o Soliciting Material Pursuant to § 240. |
|
| November 18, 2024 |
As filed with the Securities and Exchange Commission on November 18, 2024 As filed with the Securities and Exchange Commission on November 18, 2024 Registration No. |
|
| November 18, 2024 |
Exhibit 97.1 TWIST BIOSCIENCE CORPORATION COMPENSATION RECOVERY POLICY (Adopted and approved on November 2, 2023 and effective as of October 2, 2023) 1.Purpose Twist Bioscience Corporation (collectively with its subsidiaries, the “Company”) is committed to promoting high standards of honest and ethical business conduct and compliance with applicable laws, rules and regulations. As part of this com |
|
| November 18, 2024 |
Exhibit 10.14 September 9, 2022 Emily Leproust Re: AMENDED AND RESTATED EMPLOYMENT AGREEMENT Dear Emily: On behalf of Twist Bioscience Corporation, a Delaware corporation (the “Company”), I am pleased to continue your employment with the Company on the terms and conditions set forth in this amended and restated employment agreement (the “Agreement”), effective as of September 9, 2022 (the “Effecti |
|
| November 18, 2024 |
List of subsidiaries of the Registrant Exhibit 21.1 Twist Bioscience Corporation Subsidiaries Twist Bioscience Corporation has the following subsidiaries: 1. Twist Bioscience Worldwide, a Cayman Islands exempted company. 2. Genome Compiler Corporation, a Delaware corporation, which itself owns Twist Bioscience Israel Ltd. (formerly “Genome Compiler Israel Ltd.”), an Israel limited liability company. 3. Twist Bio Computing, LLC, a Delaw |
|
| November 18, 2024 |
Employment Agreement dated April 24, 2023 between Twist Bioscience Corporation and Robert Werner Exhibit 10.19 TWIST BIOSCIENCE CORPORATION April 24, 2023 Robert Werner [***] Dear Robert: Twist Bioscience Corporation, a Delaware corporation (the “Company”), is pleased to offer you employment with the Company on the terms described below. 1.Position. You will start in a full-time position as Vice President, Chief Accounting Officer and you will initially report to Jim Thorburn, CFO. A senior e |
|
| November 18, 2024 |
Exhibit 10.16 September 9, 2022 Paula Green Re: AMENDED AND RESTATED EMPLOYMENT AGREEMENT Dear Paula: On behalf of Twist Bioscience Corporation, a Delaware corporation (the “Company”), I am pleased to continue your employment with the Company on the terms and conditions set forth in this amended and restated employment agreement (the “Agreement”), effective as of September 9, 2022 (the “Effective |
|
| November 18, 2024 |
Exhibit 10.13 Twist Bioscience Corporation CONSULTING AGREEMENT This Consulting Agreement (this “Agreement”) is entered into as of October 8, 2024 (the “Effective Date”) by and between Twist Bioscience Corporation, a Delaware corporation with a place of business at 681 Gateway Boulevard South San Francisco, California 94080 (“Twist”), and James Thorburn with an address on file (“Consultant”). Cons |
|
| November 18, 2024 |
Calculation of Filing Fee Tables S-8 Twist Bioscience Corp Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Common Stock, $0. |
|
| November 18, 2024 |
Employment Agreement dated September 9, 2022 between Twist Bioscience Corporation and James Thorburn Exhibit 10.15 September 9, 2022 James Thorburn Re: AMENDED AND RESTATED EMPLOYMENT AGREEMENT Dear James: On behalf of Twist Bioscience Corporation, a Delaware corporation (the “Company”), I am pleased to continue your employment with the Company on the terms and conditions set forth in this amended and restated employment agreement (the “Agreement”), effective as of September 9, 2022 (the “Effecti |
|
| November 18, 2024 |
Exhibit 99.1 Twist Bioscience Reports Fiscal Fourth Quarter and Full Year Fiscal 2024 Financial Results — Record revenue of $313.0 million in Fiscal 2024; Increase of 28% over $245.1 million in Fiscal 2023 — — Record revenue of $84.7 million in Q4FY24; Increase of 27% over $66.9 million in Q4FY23, 7th consecutive quarter of sequential growth — — Gross margin of 45.1% in Q4FY24; Improvement of 8.5 |
|
| November 18, 2024 |
Employment Agreement dated September 9, 2022 between Twist Bioscience Corporation and William Banyai Exhibit 10.17 September 9, 2022 William Banyai Re: AMENDED AND RESTATED EMPLOYMENT AGREEMENT Dear William: On behalf of Twist Bioscience Corporation, a Delaware corporation (the “Company”), I am pleased to continue your employment with the Company on the terms and conditions set forth in this amended and restated employment agreement (the “Agreement”), effective as of September 9, 2022 (the “Effec |
|
| November 18, 2024 |
Insider Trading Compliance Program TWIST BIOSCIENCE CORPORATION INSIDER TRADING COMPLIANCE PROGRAM This Insider Trading Compliance Program (this “Program”) consists of four sections: Section I provides an overview; Section II sets forth the policies of Twist Bioscience Corporation (together with its subsidiaries, the “Company”) prohibiting insider trading; Section III explains insider trading; and Section IV consists of various procedures which have been put in place by the Company to prevent insider trading. |
|
| November 18, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 18, 2024 Twist Bioscience Corporation (Exact name of registrant as specified in its charter) Delaware 001-38720 46-2058888 (State or other jurisdiction of incorporation) (Comm |
|
| November 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-3 |
|
| November 18, 2024 |
between Twist Bioscience Corporation and Dennis Cho Exhibit 10.18 September 2, 2024 Dennis Cho Re: AMENDED AND RESTATED EMPLOYMENT AGREEMENT Dear Dennis: On behalf of Twist Bioscience Corporation, a Delaware corporation (the “Company”), I am pleased to continue your employment with the Company on the terms and conditions set forth in this amended and restated employment agreement (the “Agreement”), effective as of September 2, 2024 (the “Effective |
|
| November 8, 2024 |
EX-99 2 Rule13DJointFilingAgreement.htm JOINT FILING AGREEMENT JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) (l) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree to the joint filing of the attached Schedule 13G, and any and all amendments thereto, and expressly authorize Invesco Ltd., as the ultimate parent company of each of its undersigned subsidiarie |
|
| November 8, 2024 |
TWST / Twist Bioscience Corporation / Invesco Ltd. - SEC SCHEDULE 13G Passive Investment SC 13G 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Twist Bioscience Corp (Name of Issuer) Common Stock (Title of Class of Securities) 90184D100 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to |
|
| November 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Twist Bioscience Corporation (Name of Issuer) Common Stock (Title of Class of Securities) 90184D100 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whic |
|
| November 5, 2024 |
SC 13G/A 1 twst1028242sc13ga2.htm AMENDMENT NO. 2 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Twist Bioscience Corporation (Name of Issuer) Common Stock (Title of Class of Securities) 90184D100 (CUSIP Number) September 30, 2024 (Date of Event which Requires Filing of this Statement) Check the appr |
|
| October 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 8, 2024 Twist Bioscience Corporation (Exact name of registrant as specified in its charter) Delaware 001-38720 46-2058888 (State or other jurisdiction of incorporation) (Commis |
|
| August 9, 2024 |
Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 02)* Twist Bioscience Corporation (Name of Issuer) Common Stock (Title of Class of Securities) 90184D100 (CUSIP Number) July 31, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuan |
|
| August 2, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 2, 2024 Twist Bioscience Corporation (Exact name of registrant as specified in its charter) Delaware 001-38720 46-2058888 (State or other jurisdiction of incorporation) (Commiss |
|
| August 2, 2024 |
Exhibit 99.1 Twist Bioscience Reports Fiscal Third Quarter 2024 Financial Results – Record revenue of $81.5M in 3QFY24, an increase of 28% over $63.7M in 3QFY23 – – Gross margin improved to 43.3% in 3QFY24, increasing approximately 900 basis points over 34.4% in 3QFY23 – — Increased FY 2024 revenue guidance to approximately $310M to $311M; FY 2024 gross margin guidance at high end of the range at |
|
| August 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 00 |
|
| July 9, 2024 |
EX-99.1 EXHIBIT 1 JOINT FILING AGREEMENT The undersigned hereby agree to the joint filing of the Schedule 13G to which this Agreement is attached. Dated: 7/9/2024 ARTISAN PARTNERS ASSET MANAGEMENT INC, for itself and as the general partner of ARTISAN PARTNERS HOLDINGS LP By: Gregory K. Ramirez * ARTISAN INVESTMENTS GP LLC, for itself and as the general partner of ARTISAN PARTNERS LIMITED PARTNERSH |
|
| July 9, 2024 |
SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to Rule 13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to Rule 13d-2. Under the Securities Exchange Act of 1934 (Amendment No. 1)* Twist Bioscience Corporation (Name of Issuer) Common Shares (Title of Class of Securities) |
|
| May 2, 2024 |
Exhibit 99.1 Twist Bioscience Reports Fiscal Second Quarter 2024 Financial Results – Record revenue of $75.3M in 2QFY24, an increase of 25% over $60.2M in 2QFY23 – – Orders increased to $93.2M in 2QFY24, growth of 45% over $64.2M in 2QFY23 – — Increased FY 2024 revenue guidance to a range of $300M to $304M; Increased FY 2024 gross margin guidance to a range of 41.5 to 42.0% — — Company to host con |
|
| May 2, 2024 |
, 2024 between Twist Bioscience Corporation and James Thorburn. AMENDMENT TO EMPLOYMENT AGREEMENT This Amendment (“Amendment”) to the Employment Agreement (the “Agreement”) dated as of October 21, 2018 (the “Effective Date”), as it may have been amended from time-to-time (including on September 9, 2022), by and between Twist Bioscience Corporation, a Delaware corporation, with an address at 681 Gateway Boulevard, South San Francisco, CA 94080 (“Twist”), and James Thorburn, an individual (“Employee” or “you”), is entered into and made effective as of March 20, 2024 (the “Amendment Effective Date”). |
|
| May 2, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 2, 2024 Twist Bioscience Corporation (Exact name of registrant as specified in its charter) Delaware 001-38720 46-2058888 (State or other jurisdiction of incorporation) (Commission |
|
| May 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0 |
|
| February 13, 2024 |
TWST / Twist Bioscience Corporation / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 4)* Name of issuer: Twist Bioscience Corp Title of Class of Securities: Common Stock CUSIP Number: 90184D100 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: |
|
| February 12, 2024 |
SC 13G 1 tm245766d8sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. )* Twist Bioscience Corp (Name of Issuer) Common Stock (Title of Class of Securities) 90184D100 (CUSIP Numb |
|
| February 12, 2024 |
SC 13G 1 d755443dsc13g.htm SC 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to Rule 13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to Rule 13d-2. Under the Securities Exchange Act of 1934 (Amendment No. )* Twist Bioscience Corp (Name of Issuer) Common Stock (Title of Class of Securitie |
|
| February 12, 2024 |
SC 13G/A 1 ef20021436sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Twist Bioscience Corporation (Name of Issuer) Common Stock (Title of Class of Securities) 90184D100 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate bo |
|
| February 12, 2024 |
EX-99.1 2 d755443dex991.htm EX-99.1 EXHIBIT 1 JOINT FILING AGREEMENT The undersigned hereby agree to the joint filing of the Schedule 13G to which this Agreement is attached. Dated: 2/12/2024 ARTISAN PARTNERS ASSET MANAGEMENT INC, for itself and as the general partner of ARTISAN PARTNERS HOLDINGS LP By: Gregory K. Ramirez * ARTISAN INVESTMENTS GP LLC, for itself and as the general partner of ARTIS |
|
| February 7, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 6, 2024 Twist Bioscience Corporation (Exact name of registrant as specified in its charter) Delaware 001-38720 46-2058888 (State or other jurisdiction of incorporation) (Commi |
|
| February 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Twist Bioscience Corporation (Name of Issuer) Common Stock (Title of Class of Securities) 90184D100 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which |
|
| February 2, 2024 |
December 18, 2023 between Twist Bioscience Corporation and Adam Laponis December 18, 2023 Adam Laponis [***] Re: EMPLOYMENT AGREEMENT Dear Adam: On behalf of Twist Bioscience Corporation, a Delaware corporation (the “Company”), I am pleased to offer you employment with the Company on the terms and conditions set forth in this employment agreement (the “Agreement”), with your employment commencing on or about January 8, 2024 (the actual date you commence employment with the Company, the “Start Date”). |
|
| February 2, 2024 |
Exhibit 99.1 Twist Bioscience Reports Fiscal First Quarter 2024 Financial Results – Record revenue of $71.5M in 1QFY24, an increase of 32% over $54.2M in 1QFY23 – – Orders increased to $77.5M in 1QFY24, an increase of 19% over 1QFY23 – — Increased FY 2024 revenue guidance to $288M to $293M; Increased FY 2024 gross margin guidance to 40% to 41% — SOUTH SAN FRANCISCO, Calif. - (February 2, 2024) — T |
|
| February 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 2, 2024 Twist Bioscience Corporation (Exact name of registrant as specified in its charter) Delaware 001-38720 46-2058888 (State or other jurisdiction of incorporation) (Commi |
|
| February 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number |
|
| January 29, 2024 |
TWST / Twist Bioscience Corporation / ARK Investment Management LLC - SC 13G/A Passive Investment SC 13G/A 1 tm244117d25sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 4)* Twist Bioscience Corporation (Name of Issuer) Common stock (Title of Class of Securities) 90184D100 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box |
|
| January 25, 2024 |
Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 01)* Twist Bioscience Corporation (Name of Issuer) Common Stock (Title of Class of Securities) 90184D100 (CUSIP Number) December 29, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pur |
|
| January 25, 2024 |
Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 01)* Twist Bioscience Corporation (Name of Issuer) Common Stock (Title of Class of Securities) 90184D100 (CUSIP Number) December 29, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pur |
|
| January 22, 2024 |
TWST / Twist Bioscience Corporation / INTEGRATED CORE STRATEGIES (US) LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT NO. 1) TWIST BIOSCIENCE CORPORATION (Name of Issuer) COMMON STOCK, PAR VALUE $0.00001 PER SHARE (Title of Class of Securities) 90184D100 (CUSIP Number) DECEMBER 31, 2023 (Date of event which requires filing of this statement) Check the appropriate box to designa |
|
| January 5, 2024 |
TABLE OF CONTENTS SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy Statement o Definitive Additional Materials o Soliciting Material Pursuant to § 240. |
|
| January 5, 2024 |
Twist Bioscience Appoints Adam Laponis as Chief Financial Officer Exhibit 99.1 Twist Bioscience Appoints Adam Laponis as Chief Financial Officer SOUTH SAN FRANCISCO, – January 5, 2024 – Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the appointment of Adam Laponis as chief financial officer. Mr. Laponis brings experience across sma |
|
| January 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 5, 2024 Twist Bioscience Corporation (Exact name of registrant as specified in its charter) Delaware 001-38720 46-2058888 (State or other jurisdiction of incorporation) (Commis |
|
| November 21, 2023 |
As filed with the Securities and Exchange Commission on November 21, 2023 As filed with the Securities and Exchange Commission on November 21, 2023 Registration No. |
|
| November 21, 2023 |
List of subsidiaries of the Registrant Exhibit 21.1 Twist Bioscience Corporation Subsidiaries Twist Bioscience Corporation has the following subsidiaries: 1. Twist Bioscience Worldwide, a Cayman Islands exempted company. 2. Genome Compiler Corporation, a Delaware corporation, which itself owns Twist Bioscience Israel Ltd. (formerly “Genome Compiler Israel Ltd.”), an Israel limited liability company. 3. Twist Bio Computing, LLC, a Delaw |
|
| November 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-3 |
|
| November 21, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Twist Bioscience Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0. |
|
| November 17, 2023 |
Exhibit 99.1 Twist Bioscience Reports Fiscal Fourth Quarter and Full Year Fiscal 2023 Financial Results - Record revenue of $245.1 million in Fiscal 2023; Increase of 20% over $203.6 million in Fiscal 2022 - - Orders increased to $264 million in Fiscal 2023; Increase of 17% over $226.4 million in Fiscal 2022 - — Expect revenue in the range of $285 million to $290 million for full year Fiscal 2024 |
|
| November 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 17, 2023 Twist Bioscience Corporation (Exact name of registrant as specified in its charter) Delaware 001-38720 46-2058888 (State or other jurisdiction of incorporation) (Comm |
|
| September 8, 2023 |
TWST / Twist Bioscience Corp / INTEGRATED CORE STRATEGIES (US) LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 TWIST BIOSCIENCE CORPORATION (Name of Issuer) COMMON STOCK, PAR VALUE $0.00001 PER SHARE (Title of Class of Securities) 90184D100 (CUSIP Number) SEPTEMBER 1, 2023 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursua |
|
| August 25, 2023 |
Exhibit 99.1 TWIST BIOSCIENCE CORPORATION INDUCEMENT EQUITY INCENTIVE PLAN 1. Purposes of the Plan. The purposes of this Plan are to attract the best available personnel to ensure the Company’s success and accomplish the Company’s goals by providing a material inducement to individuals entering or re-entering into employment with the company or any Parent or Subsidiary of the Company. T |
|
| August 25, 2023 |
As filed with the Securities and Exchange Commission on August 25, 2023 As filed with the Securities and Exchange Commission on August 25, 2023 Registration No. |
|
| August 25, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Twist Bioscience Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0. |
|
| August 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 00 |
|
| August 4, 2023 |
Exhibit 99.1 Twist Bioscience Reports Fiscal Third Quarter 2023 Financial Results - Record revenue of $63.7M in 3QFY23; Increase of 14% over $56.1M in Fiscal 2022 – - Orders increased 7% in 3QFY23 over fiscal 2022 to $63.8M - SOUTH SAN FRANCISCO, Calif. - (August 4, 2023) — Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality syn |
|
| August 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 3, 2023 Twist Bioscience Corporation (Exact name of registrant as specified in its charter) Delaware 001-38720 46-2058888 (State or other jurisdiction of incorporation) (Commiss |
|
| August 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 4, 2023 ( May 3, 2023) Twist Bioscience Corporation (Exact name of registrant as specified in its charter) Delaware 001-38720 46-2058888 (State or other juri |
|
| June 5, 2023 |
As filed with the Securities and Exchange Commission on June 5, 2023 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on June 5, 2023 Registration No. |
|
| June 5, 2023 |
Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) Twist Bioscience Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward |
|
| June 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001 |
|
| May 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 23, 2023 Twist Bioscience Corporation (Exact name of registrant as specified in its charter) Delaware 001-38720 46-2058888 (State or other jurisdiction of incorporation) (Commissio |
|
| May 23, 2023 |
Twist Bioscience Appoints Robert Werner as Chief Accounting Officer Exhibit 99.1 Twist Bioscience Appoints Robert Werner as Chief Accounting Officer SOUTH SAN FRANCISCO, Calif. – May 23, 2023 – Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the appointment of Robert Werner as chief accounting officer. “Rob has a proven track record o |
|
| May 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0 |
|
| May 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 3, 2023 Twist Bioscience Corporation (Exact name of registrant as specified in its charter) Delaware 001-38720 46-2058888 (State or other jurisdiction of incorporation) (Commission |
|
| May 5, 2023 |
Exhibit 99.1 Twist Bioscience Reports Fiscal Second Quarter 2023 Financial Results – Record revenue of $60.2M in 2QFY23; up 25% over $48.1M in 2QFY22 – – Orders increased to $64.2M in 2QFY23; up 17% over 2QFY22 – - Decisive Actions to Accelerate Path to Profitability - SOUTH SAN FRANCISCO, Calif. - (May 5, 2023) — Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed |
|
| April 10, 2023 |
TWST / Twist Bioscience Corp / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 3)* Name of issuer: Twist Bioscience Corp. Title of Class of Securities: Common Stock CUSIP Number: 90184D100 Date of Event Which Requires Filing of this Statement: March 31, 2023 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ |
|
| March 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 23, 2023 Twist Bioscience Corporation (Exact name of registrant as specified in its charter) Delaware 001-38720 46-2058888 (State or other jurisdiction of incorporation) (Commiss |
|
| February 13, 2023 |
TWST / Twist Bioscience Corp / Capital World Investors - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* Twist Bioscience Corp. (Name of Issuer) Common Stock (Title of Class of Securities) 90184D100 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this |
|
| February 10, 2023 |
TWST / Twist Bioscience Corp / ARK Investment Management LLC - SC 13G/A Passive Investment SC 13G/A 1 tm235555d33sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 3)* Twist Bioscience Corporation (Name of Issuer) Common stock (Title of Class of Securities) 90184D100 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box |
|
| February 10, 2023 |
TWST / Twist Bioscience Corp / Nikko Asset Management Americas, Inc. - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. n/a)* Twist Bioscience Corporation (Name of Issuer) Common Stock (Title of Class of Securities) 90184D100 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whi |
|
| February 9, 2023 |
TWST / Twist Bioscience Corp / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv02099-twistbiosciencecorp.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2)* Name of issuer: Twist Bioscience Corp. Title of Class of Securities: Common Stock CUSIP Number: 90184D100 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to d |
|
| February 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 7, 2023 Twist Bioscience Corporation (Exact name of registrant as specified in its charter) Delaware 001-38720 46-2058888 (State or other jurisdiction of incorporation) (Commi |
|
| February 7, 2023 |
Exhibit 10.1 October 26, 2022 Patrick Finn Re: AMENDED AND RESTATED EMPLOYMENT AGREEMENT Dear Patrick: On behalf of Twist Bioscience Corporation, a Delaware corporation (the “Company”), I am pleased to continue your employment with the Company on the terms and conditions set forth in this amended and restated employment agreement (the “Agreement”), effective as of October 1, 2022 (the “Effective D |
|
| February 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number |
|
| February 3, 2023 |
TWST / Twist Bioscience Corp / Sumitomo Mitsui Trust Holdings, Inc. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. n/a)* Twist Bioscience Corporation (Name of Issuer) Common Stock (Title of Class of Securities) 90184D100 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whi |
|
| February 3, 2023 |
Exhibit 99.1 Twist Bioscience Reports Fiscal First Quarter 2023 Financial Results – Revenue of $54.2M in 1QFY23 increased 29% over $42.0M in 1QFY22 – – Orders increased to $64.7M in 1QFY23, an increase of 30% over 1QFY22 – SOUTH SAN FRANCISCO, Calif. - (February 3, 2023) — Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synt |
|
| February 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 3, 2023 Twist Bioscience Corporation (Exact name of registrant as specified in its charter) Delaware 001-38720 46-2058888 (State or other jurisdiction of incorporation) (Commi |
|
| January 13, 2023 |
SC 13G 1 TwistBioscienceCorporati.htm FILING TWIST BIOSCIENCE CORPORATION UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Twist Bioscience Corporation (Name of Issuer) Common Stock (Title of Class of Securities) 90184D100 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Sta |
|
| January 6, 2023 |
TABLE OF CONTENTS SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? ? Definitive Proxy Statement ? ? Definitive Additional Materials ? ? Soliciting Material Pursuant to ? 240. |
|
| November 28, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Twist Bioscience Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0. |
|
| November 28, 2022 |
As filed with the Securities and Exchange Commission on November 28, 2022 As filed with the Securities and Exchange Commission on November 28, 2022 Registration No. |
|
| November 28, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-3 |
|
| November 28, 2022 |
List of subsidiaries of the Registrant Exhibit 21.1 Twist Bioscience Corporation Subsidiaries Twist Bioscience Corporation has the following subsidiaries: 1. Twist Bioscience Worldwide, a Cayman Islands exempted company. 2. Genome Compiler Corporation, a Delaware corporation, which itself owns Twist Bioscience Israel Ltd. (formerly ?Genome Compiler Israel Ltd.?), an Israel limited liability company. 3. Twist Bio Computing, LLC, a Delaw |
|
| November 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 17, 2022 Twist Bioscience Corporation (Exact name of registrant as specified in its charter) Delaware 001-38720 46-2058888 (State or other jurisdiction of incorporation) (Comm |
|
| November 18, 2022 |
Exhibit 99.1 Twist Bioscience Reports Fiscal Fourth Quarter and Full Year Fiscal 2022 Financial Results - Record revenue of $203.6 million in Fiscal 2022; Increase of 54% over $132.3 million in Fiscal 2021 – - Orders increased to $226 million in Fiscal 2022; Increase of 42% over $160 million in Fiscal 2021 - — Expect revenue in the range of $261 million to $269 million for full year Fiscal 2023 - |
|
| November 18, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 18, 2022 Twist Bioscience Corporation (Exact name of registrant as specified in its charter) Delaware 001-38720 46-2058888 (State or other jurisdiction of incorporation) (Comm |
|
| November 18, 2022 |
Exhibit 3.1 BYLAWS OF TWIST BIOSCIENCE CORPORATION (As Amended and Restated Effective November 17, 2022) TABLE OF CONTENTS Page ARTICLE I CORPORATE OFFICES 1 1.1 REGISTERED OFFICE 1 1.2 OTHER OFFICES 1 ARTICLE II MEETINGS OF STOCKHOLDERS 1 2.1 PLACE OF MEETINGS 1 2.2 ANNUAL MEETING 1 2.3 SPECIAL MEETING 4 2.4 NOTICE OF STOCKHOLDER?S MEETINGS; AFFIDAVIT OF NOTICE 4 2.5 QUORUM 5 2.6 ORGANIZATION 5 2 |
|
| November 16, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 15, 2022 Twist Bioscience Corporation (Exact name of registrant as specified in its charter) Delaware 001-38720 46-2058888 (State or other jurisdiction of incorporation) (Comm |
|
| November 16, 2022 |
Exhibit 99.1 Twist Bioscience Addresses Misleading Short-Seller Report Twist to report fiscal Q4 and full year 2022 financial results before market Friday, November 18, and host a conference call at 8:00 a.m. Eastern Time SOUTH SAN FRANCISCO, Calif. – November 15, 2022 – Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthe |
|
| October 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 25, 2022 Twist Bioscience Corporation (Exact name of registrant as specified in its charter) Delaware 001-38720 46-2058888 (State or other jurisdiction of incorporation) (Commi |
|
| October 26, 2022 |
Exhibit 99.1 Twist Bioscience Promotes Patrick Finn, Ph.D., to President and Chief Operating Officer Dr. Finn previously served as Twist?s chief commercial officer SOUTH SAN FRANCISCO, Calif. ? October 26, 2022 ? Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the pro |
|
| August 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 00 |
|
| August 5, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 5, 2022 Twist Bioscience Corporation (Exact name of registrant as specified in its charter) Delaware 001-38720 46-2058888 (State or other jurisdiction of incorporation) (Commiss |
|
| August 5, 2022 |
Exhibit 99.1 Twist Bioscience Reports Fiscal Third Quarter 2022 Financial Results - Record revenue of $56.1M in 3QFY22; Increase of 60% over $35.0M in Fiscal 2021 ? - Orders increased 53% in 3QFY22 over fiscal 2021 to $59.7M - ? Increases revenue guidance to $203 million for full year fiscal 2022 - SOUTH SAN FRANCISCO, Calif. - (August 5, 2022) ? Twist Bioscience Corporation (NASDAQ: TWST), a comp |
|
| June 9, 2022 |
TWST / Twist Bioscience Corp / ARK Investment Management LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. |
|
| May 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0 |
|
| May 5, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 5, 2022 Twist Bioscience Corporation (Exact name of registrant as specified in its charter) Delaware 001-38720 46-2058888 (State or other jurisdiction of incorporation) (Commission |
|
| May 5, 2022 |
Exhibit 99.1 Twist Bioscience Reports Second Quarter 2022 Financial Results - Record revenue of $48.1M in 2QFY22; Increase of 54% over $31.2M in Fiscal 2021 ? - Orders Increased 32% in 2QFY22 over Fiscal 2021 to $55.0M - SOUTH SAN FRANCISCO, Calif. - (May 5, 2022) ? Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic D |
|
| April 22, 2022 |
Twist Bioscience Announces Promotions and Changes to Executive Leadership Team Exhibit 99.1 Twist Bioscience Announces Promotions and Changes to Executive Leadership Team SOUTH SAN FRANCISCO, CA ? April 21, 2022 ? Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the promotion of Tracey Mullen, MBA to senior vice president of operations and Nimish |
|
| April 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 20, 2022 Twist Bioscience Corporation (Exact name of registrant as specified in its charter) Delaware 001-38720 46-2058888 (State or other jurisdiction of incorporation) (Commiss |
|
| March 10, 2022 |
TWST / Twist Bioscience Corp / FMR LLC Passive Investment SCHEDULE 13G Amendment No.0 TWIST BIOSCIENCE CORP COMMON STOCK Cusip #90184D100 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #90184D100 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 5,944,797 Item 6: 0 Item 7: 5,950,181 Item 8: 0 Item 9: 5,950,181 Item 11: |
|
| March 9, 2022 |
Exhibit 16.1 March 9, 2022 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read the statements made by Twist Bioscience Corporation (copy attached), which we understand will be filed with the Securities and Exchange Commission, pursuant to Item 4.01 of Form 8-K of Twist Bioscience Corporation dated March 3, 2022. We agree with the statements concer |
|
| March 9, 2022 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 3, 2022 Twist Bioscience Corporation (Exact name of registrant as specified in its charter) Delaware 001-38720 46-2058888 (State or other jurisdiction of incorporation) (Commissi |
|
| February 15, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 10, 2022 Twist Bioscience Corporation (Exact name of registrant as specified in its charter) Delaware 001-38720 46-2058888 (State or other jurisdiction of incorporation) (Comm |
|
| February 15, 2022 |
EX-1.1 2 tm226786d1ex1-1.htm EXHIBIT 1.1 Exhibit 1.1 TWIST BIOSCIENCE CORPORATION 4,545,454 Shares of Common Stock Underwriting Agreement February 10, 2022 J. P. Morgan Securities LLC Goldman Sachs & Co. LLC Cowen and Company, LLC As Representatives of the several Underwriters listed in Schedule 1 hereto c/o J. P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 c/o Goldman Sachs |
|
| February 14, 2022 |
EX-FILING FEES 2 tm225889d3ex-filingfees.htm EX-FILING FEES EX-FILING FEES Calculation of Filing Fee Table 424(b)(5) (Form Type) Twist Bioscience Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate |
|
| February 14, 2022 |
424B5 1 tm225889-3424b5.htm 424B5 TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-238906 Prospectus supplement (To the Prospectus dated June 3, 2020) 4,545,454 shares Common stock Twist Bioscience Corporation is offering 4,545,454 shares of our common stock. Our common stock is listed on the Nasdaq Global Select Market under the symbol “TWST.” The last reported sale price |
|
| February 11, 2022 |
TWST / Twist Bioscience Corp / Capital World Investors - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Twist Bioscience Corp. (Name of Issuer) Common Stock (Title of Class of Securities) 90184D100 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this |
|
| February 10, 2022 |
TWST / Twist Bioscience Corp / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: Twist Bioscience Corp. Title of Class of Securities: Common Stock CUSIP Number: 90184D100 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed |
|
| February 9, 2022 |
424B5 1 tm225889-1424b5.htm 424B5 TABLE OF CONTENTS The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities and we are not soliciting an offer to buy these securities in any state where the offer or sale is not permitted. Filed Pursuant to Rule 424 |
|
| February 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number |
|
| February 9, 2022 |
TWST / Twist Bioscience Corp / ARK Investment Management LLC - SC 13G/A Passive Investment SC 13G/A 1 tm225659d46sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* Twist Bioscience Corporation (Name of Issuer) Common stock (Title of Class of Securities) 90184D100 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box |
|
| February 9, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 8, 2022 Twist Bioscience Corporation (Exact name of registrant as specified in its charter) Delaware 001-38720 46-2058888 (State or other jurisdiction of incorporation) (Commi |
|
| February 4, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 4, 2022 Twist Bioscience Corporation (Exact name of registrant as specified in its charter) Delaware 001-38720 46-2058888 (State or other jurisdiction of incorporation) (Commi |
|
| February 4, 2022 |
Exhibit 99.1 Twist Bioscience Reports First Quarter 2022 Financial Results - Record Revenues of $42M; Increase of 49% over $28.2M in Fiscal 2021 - - Orders Increased 48% to $49.6M - - Increased Revenue Guidance for Fiscal 2022 - SOUTH SAN FRANCISCO, Calif. ? February 4, 2022 ? Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality |
|
| January 4, 2022 |
Proxy Statement, filed with the SEC on January 4, 2022; TABLE OF CONTENTS SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? ? Definitive Proxy Statement ? ? Definitive Additional Materials ? ? Soliciting Material Pursuant to ? 240. |
|
| December 2, 2021 |
Exhibit 4.1 Confidential REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this ?Agreement?), dated as of December 1, 2021, is made by and between Twist Bioscience Corporation, a Delaware corporation (?Parent?), Edgemont Capital Partners, L.P. (?Edgemont?) and each Holder set forth on the signature pages hereto (or who delivers an executed joinder to this agreement in the form of E |
|
| December 2, 2021 |
424B7 1 d278266d424b7.htm 424B7 Table of Contents Filed pursuant to Rule 424(b)(7) Registration No. 333-238906 CALCULATION OF REGISTRATION FEE Title of each Class of Securities to be Registered Amount to be Registered Proposed Maximum Offering Price Per Share Proposed Maximum Aggregate Offering Price Amount of Registration Fee(1) Common Stock, $0.00001 par value per share 1,346,287 $95.23 $128,649 |
|
| December 2, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 1, 2021 Twist Bioscience Corporation (Exact name of registrant as specified in its charter) Delaware 001-38720 46-2058888 (State or other jurisdiction of incorporation) (Commi |
|
| November 23, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 5, 2021 Twist Bioscience Corporation (Exact name of registrant as specified in its charter) Delaware 001-38720 46-2058888 (State or other jurisdiction of inc |
|
| November 23, 2021 |
List of subsidiaries of the Registrant Exhibit 21.1 Twist Bioscience Corporation Subsidiaries Twist Bioscience Corporation has the following subsidiaries: 1. Twist Bioscience Worldwide, a Cayman Islands exempted company. 2. Genome Compiler Corporation, a Delaware corporation, which itself owns Twist Bioscience Israel Ltd. (formerly ?Genome Compiler Israel Ltd.?), an Israeli company. 3. Twist Bio Computing, LLC, a Delaware limited liabi |
|
| November 23, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-3 |
|
| November 22, 2021 |
Exhibit 99.1 Twist Bioscience Enters into Definitive Agreement to Acquire Abveris, Bolstering Biopharma Capabilities - Acquisition Will Add In Vivo Antibody Discovery Platform ? - Conference Call at 8:00am ET - SOUTH SAN FRANCISCO, Calif. ? November 22, 2021 - Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA usi |
|
| November 22, 2021 |
Unregistered Sales of Equity Securities, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 19, 2021 Twist Bioscience Corporation (Exact name of registrant as specified in its charter) Delaware 001-38720 46-2058888 (State or other jurisdiction of incorporation) (Comm |
|
| November 22, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 22, 2021 Twist Bioscience Corporation (Exact name of registrant as specified in its charter) Delaware 001-38720 46-2058888 (State or other jurisdiction of incorporation) (Comm |
|
| November 22, 2021 |
Exhibit 99.1 Twist Bioscience Reports Fourth Quarter and Full Year Fiscal 2021 Financial Results - Record Revenues in Fiscal 2021 of $132.3M; Increase of 47% over $90.1M in Fiscal 2020 - - Growth Driven by Strength in SynBio, NGS, Biopharma Businesses - - Expect Revenue of $183M to $193M for Fiscal 2022 - SOUTH SAN FRANCISCO, Calif. ? November 22, 2021 ? Twist Bioscience Corporation (NASDAQ: TWST) |
|
| August 9, 2021 |
August 9, 2021 (Registration No. 333-258639) As filed with the Securities and Exchange Commission on August 9, 2021 Registration No. |
|
| August 9, 2021 |
Twist Bioscience Appoints Drug Discovery Leader Melissa Starovasnik, Ph.D., to Board of Directors Exhibit 99.1 Twist Bioscience Appoints Drug Discovery Leader Melissa Starovasnik, Ph.D., to Board of Directors SOUTH SAN FRANCISCO, Calif. ? August 6, 2021 ? Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced it appointed Melissa Starovasnik, Ph.D. to its board of direct |
|
| August 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 5, 2021 Twist Bioscience Corporation (Exact name of registrant as specified in its charter) Delaware 001-38720 46-2058888 (State or other jurisdiction of incorporation) (Commiss |
|
| August 6, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 6, 2021 Twist Bioscience Corporation (Exact name of registrant as specified in its charter) Delaware 001-38720 46-2058888 (State or other jurisdiction of incorporation) (Commiss |
|
| August 6, 2021 |
Exhibit 99.1 Twist Bioscience Reports Third Quarter Fiscal 2021 Financial Results - Revenue Growth of 65% over Fiscal 2020 Third Quarter - - Order Growth of 58% Year over Year - - Gross Margin of 40% for the Quarter - SOUTH SAN FRANCISCO, Calif. ? August 6, 2021 ? Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA |
|
| June 30, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 30, 2021 Twist Bioscience Corporation (Exact name of registrant as specified in its charter) Delaware 001-38720 46-2058888 (State or other jurisdiction of incorporation) (Commissi |
|
| June 30, 2021 |
Table of Contents Filed pursuant to Rule 424(b)(7) Registration No. 333-238906 CALCULATION OF REGISTRATION FEE Title of each Class of Securities to be Registered Amount to be Registered Proposed Maximum Offering Price Per Share Proposed Maximum Aggregate Offering Price Amount of Registration Fee(1) Common Stock, $0.00001 par value per share 334,932 $120.17 $40,248,779 $4,392 (1) The registration f |
|
| June 30, 2021 |
Exhibit 4.1 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this ?Agreement?), dated as of June 14, 2021, is made by and among Twist Bioscience Corporation, a Delaware corporation (?Parent?), and Shareholder Representative Services LLC, a Colorado limited liability company (?Securityholder Representative?), for the benefit of the Holders (as defined below). WHEREAS, Parent, Chase |
|
| May 7, 2021 |
Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| May 6, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 6, 2021 Twist Bioscience Corporation (Exact name of registrant as specified in its charter) Delaware 001-38720 46-2058888 (State or other jurisdiction of incorporation) (Commission |
|
| May 6, 2021 |
Exhibit 99.1 Twist Bioscience Reports Second Quarter Fiscal 2021 Financial Results - Revenue Growth of 62% over Fiscal 2020 Second Quarter - - Order Growth of 69% Year over Year - - Gross Margin of 39% for the Quarter - SOUTH SAN FRANCISCO, Calif. ? May 6, 2021 ? Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA |
|
| April 16, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 13, 2021 Twist Bioscience Corporation (Exact name of registrant as specified in its charter) Delaware 001-38720 46-2058888 (State or other jurisdiction of incorporation) (Commiss |
|
| April 16, 2021 |
Exhibit 10.1 FIRST AMENDMENT TO LEASE THIS FIRST AMENDMENT TO LEASE (this ?Amendment?) is made this 13th day of April, 2021 (the ?Effective Date?) by and between PWII Owner, LLC, a Delaware limited liability company (?Landlord?), and Twist Bioscience Corporation, a Delaware corporation (?Tenant?). RECITALS A. Landlord and Tenant are parties to that certain Lease dated December 18, 2020 (the ?Lease |
|
| March 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No. 2)* Under the Securities Exchange Act of 1934 Twist Bioscience Corporation (Name of Issuer) Common stock, par value $0.00001 per share (Title of Class of Securities) 90184D100 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to design |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) Twist Bioscience Corporation (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 90184D100 (CUSIP Number) December 31, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designa |
|
| February 16, 2021 |
JOINT FILING AGREEMENT PURSUANT TO RULE 13D-1(K)(1) Exhibit 99.1 JOINT FILING AGREEMENT PURSUANT TO RULE 13D-1(K)(1) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing an additional joint filing agreement. The undersigned |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Twist Bioscience Corp. (Name of Issuer) Common Stock (Title of Class of Securities) 90184D100 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this S |
|
| February 10, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: Twist Bioscience Corp. Title of Class of Securities: Common Stock CUSIP Number: 90184D100 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d-1(b) ☐ |
|
| February 9, 2021 |
Submission of Matters to a Vote of Security Holders - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 3, 2021 Twist Bioscience Corporation (Exact name of registrant as specified in its charter) Delaware 001-38720 46-2058888 (State or other jurisdiction of incorporation) (Commi |
|
| February 9, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number |
|
| February 4, 2021 |
Twist Bioscience Reports First Quarter Fiscal 2021 Financial Results EX-99.1 Exhibit 99.1 Twist Bioscience Reports First Quarter Fiscal 2021 Financial Results SOUTH SAN FRANCISCO, Calif. – February 4, 2021 – Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today reported financial results and business highlights for the first quarter of fiscal 2021 end |
|
| February 4, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 4, 2021 Twist Bioscience Corporation (Exact name of registrant as specified in its charter) Delaware 001-38720 46-205888 (State or other jurisdiction of incorporation) (Co |
|
| February 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 – Exit Filing)* Twist Bioscience Corporation (Name of Issuer) Common Stock par value $0.00001 per share (Title of Class of Securities) 90184D100 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of This Statement) Check the appropriate |
|
| January 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. |
|
| January 7, 2021 |
DEF 14A Table of Contents SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material Pursuant to § 240. |
|
| January 6, 2021 |
Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 01)* Twist Bioscience Corporation (Name of Issuer) Common Stock (Title of Class of Securities) 90184D100 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pur |
|
| December 23, 2020 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits - 8-K 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 18, 2020 Twist Bioscience Corporation (Exact name of registrant as specified in its charter) Delaware 001-38720 46-205888 (State or other jurisdiction of incorporation) (C |
|
| December 23, 2020 |
EX-10.1 Exhibit 10.1 LEASE AGREEMENT by and between Twist Bioscience Corporation (“Tenant”) and PWII Owner, LLC (“Landlord”) , 2020 ParkWorks Industry Center Wilsonville, Oregon 1. Demise and Premises 1 1.1 Demise 1 1.2 Premises and Associated Rights 1 1.3 Commencement and Expiration Dates 1 1.4 Right to Holdover 2 1.5 Right of First Refusal 2 1.6 Project Improvements 4 2. Rent 4 2 |
|
| December 4, 2020 |
EX-1.1 Exhibit 1.1 TWIST BIOSCIENCE CORPORATION 2,802,272 Shares of Common Stock Underwriting Agreement December 2, 2020 J. P. Morgan Securities LLC Goldman Sachs & Co. LLC Cowen and Company, LLC Evercore Group L.L.C. As Representatives of the several Underwriters listed in Schedule 1 hereto c/o J. P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 c/o Goldman Sachs & Co. LLC 200 |
|
| December 4, 2020 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits - 8-K 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 2, 2020 Twist Bioscience Corporation (Exact name of registrant as specified in its charter) Delaware 001-38720 46-2058888 (State or other jurisdiction of incorporation) (C |
|
| December 4, 2020 |
424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-238906 CALCULATION OF REGISTRATION FEE Title of each Class of Securities to be Registered Amount to be Registered Proposed Maximum Offering Price per Share Proposed Maximum Aggregate Offering Price Amount of Registration Fee(2) Common Stock, $0.00001 par value per share 3,211,362(1) $110.00 $353,249,820 $38,539.58 (1) In |
|
| December 1, 2020 |
Joint book running managers J.P. Morgan Goldman Sachs & Co. LLC Cowen Evercore ISI Lead manager 424B5 Table of Contents Filed Pursuant to Rule (424)(5) Registration No. 333-238906 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities and we are not soliciting an offer to buy these securities in any state where the offer or sale is not permit |
|
| November 27, 2020 |
List of subsidiaries of the Registrant. EX-21.1 Exhibit 21.1 Twist Bioscience Corporation Subsidiaries Twist Bioscience Corporation has the following subsidiaries: 1. Twist Bioscience Worldwide, a Cayman Islands exempted company. 2. Genome Compiler Corporation, a Delaware corporation, which itself owns Twist Bioscience Israel Ltd. (formerly “Genome Compiler Israel Ltd.”), an Israeli company. 3. Twist Bio Computing, LLC, a Delaware limit |
|
| November 27, 2020 |
10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| November 27, 2020 |
EX-4.5 Exhibit 4.5 Description of Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 Twist Bioscience Corporation (“Twist,” “we,” “our,” “us,” or the “Company”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: common stock. The following is a description of the material terms of our Amended and Restated Cer |
|
| November 23, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 23, 2020 Twist Bioscience Corporation (Exact name of registrant as specified in its charter) Delaware 001-38720 46-205888 (State or other jurisdiction of incorporation) (C |
|
| November 23, 2020 |
EX-99.1 Exhibit 99.1 Twist Bioscience Reports Fourth Quarter and Full Year Fiscal 2020 Financial Results — Fiscal 2020 Revenues of $90.1M; Increase of 66% over $54.4M in Fiscal 2019 — — Strong Growth in Synthetic Biology, NGS Businesses — — Twist Biopharma Established 13 Partnerships, 8 with Milestones and/or Royalties in FY20 — — Expect Revenue of $110M to $118M for Fiscal 2021 — SOUTH SAN FRANCI |
|
| August 12, 2020 |
10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 6, 2020 |
EX-99.1 Exhibit 99.1 Twist Bioscience Reports Third Quarter Fiscal 2020 Financial Results — Strong Third Quarter Fiscal 2020 Revenues of $21.2M; Increase of 56% over Third Quarter Fiscal 2019 – SOUTH SAN FRANCISCO, Calif. – August 6, 2020 – Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platf |
|
| August 6, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 6, 2020 Twist Bioscience Corporation (Exact name of registrant as specified in its charter) Delaware 001-38720 46-205888 (State or other jurisdiction of incorporation) (Comm |
|
| June 5, 2020 |
EX-1.1 Exhibit 1.1 Execution Version TWIST BIOSCIENCE CORPORATION 3,030,303 Shares of Common Stock Underwriting Agreement June 3, 2020 J. P. Morgan Securities LLC Cowen and Company, LLC Evercore Group L.L.C. As Representatives of the several Underwriters listed in Schedule 1 hereto c/o J. P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 c/o Cowen and Company, LLC 599 Lexington |
|
| June 5, 2020 |
424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-238906 CALCULATION OF REGISTRATION FEE Title of each Class of Securities to be Registered Amount to be Registered Proposed Maximum Offering Price per Share Proposed Maximum Aggregate Offering Price Amount of Registration Fee(2) Common Stock, $0.00001 par value per share 3,484,848(1) $33.00 $114,999,984 $14,927 (1) Includ |
|
| June 5, 2020 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 3, 2020 Twist Bioscience Corporation (Exact name of registrant as specified in its charter) Delaware 001-38720 46-2058888 (State or other jurisdiction of incorporation) (Commi |
|
| June 3, 2020 |
Joint book running managers J.P. Morgan Cowen Evercore ISI Lead manager Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-238906 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities and we are not soliciting an offer to buy these securities in any state where the offer or sale is not permitted. |
|
| June 3, 2020 |
S-3ASR Table of Contents As filed with the Securities and Exchange Commission on June 3, 2020 Registration No. |
|
| May 13, 2020 |
10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| May 7, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 7, 2020 Twist Bioscience Corporation (Exact name of registrant as specified in its charter) Delaware 001-38720 46-205888 (State or other jurisdiction of incorporation) (Commiss |
|
| May 7, 2020 |
EX-99.1 Exhibit 99.1 Twist Bioscience Reports Second Quarter Fiscal 2020 Financial Results — Strong Second Quarter Fiscal 2020 Revenues of $19.3M; Increase of 42% over Second Quarter Fiscal 2019 – SOUTH SAN FRANCISCO, Calif. – May 7, 2020 – Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platf |
|
| February 21, 2020 |
Joint book running managers J.P. Morgan Cowen Evercore ISI Lead manager 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-234538 Prospectus supplement (To the Prospectus dated November 6, 2019) 4,642,857 shares Common stock Twist Bioscience Corporation is offering 4,642,857 shares of our common stock. Our common stock is listed on the Nasdaq Global Select Market under the symbol “TWST.” The last reported sale price of our common stock on th |
|
| February 20, 2020 |
EX-1.1 Exhibit 1.1 Execution Version TWIST BIOSCIENCE CORPORATION 4,642,857 Shares of Common Stock Underwriting Agreement February 19, 2020 J. P. Morgan Securities LLC Cowen and Company, LLC Evercore Group L.L.C. As Representatives of the several Underwriters listed in Schedule 1 hereto c/o J. P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 c/o Cowen and Company, LLC 599 Lexin |
|
| February 20, 2020 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 19, 2020 Twist Bioscience Corporation (Exact name of registrant as specified in its charter) Delaware 001-38720 46-2058888 (State or other jurisdiction of incorporati |
|
| February 20, 2020 |
TWST / Twist Bioscience Corp / Illumina Inc - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No. 1 )* Under the Securities Exchange Act of 1934 Twist Bioscience Corporation (Name of Issuer) Common stock, par value $0.00001 per share (Title of Class of Securities) 90184D100 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desig |
|
| February 18, 2020 |
Joint book running managers J.P. Morgan Cowen Evercore ISI Lead manager Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-234538 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities and we are not soliciting an offer to buy these securities in any state where the offer or sale is not permitted. |
|
| February 14, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Twist Bioscience Corporation (Name of Issuer) Common Stock par value $0.00001 per share (Title of Class of Securities) 90184D100 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designa |
|
| February 11, 2020 |
February 11, 2020 (Registration No. 333-236373) As filed with the Securities and Exchange Commission on February 11, 2020 Registration No. |
|
| February 10, 2020 |
10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| February 10, 2020 |
EX-10.1 Exhibit 10.1 SETTLEMENT AGREEMENT This Settlement Agreement (Agreement) is made and entered into this 6th day of February 2020 (Effective Date) by and between Agilent Technologies, Inc., a Delaware corporation (Agilent); Twist Bioscience Corp., a Delaware corporation (Twist); Emily Leproust, an individual (Leproust); Siyuan Chen, an individual (Chen); and Solange Glaize, an ind |
|
| February 7, 2020 |
Submission of Matters to a Vote of Security Holders 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 4, 2020 Twist Bioscience Corporation (Exact name of registrant as specified in its charter) Delaware 001-38720 46-205888 (State or other jurisdiction of incorporation) (Co |
|
| February 6, 2020 |
EX-99.1 Exhibit 99.1 Twist Bioscience Reports First Quarter Fiscal 2020 Financial Results — First Quarter Fiscal 2020 Revenues of $17.2M; Increase of 49% over First Quarter Fiscal 2019 – — Reaches Settlement Agreement with Agilent in Litigation — SOUTH SAN FRANCISCO, Calif. – February 6, 2020 – Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offerin |
|
| February 6, 2020 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 6, 2020 Twist Bioscience Corporation (Exact name of registrant as specified in its charter) Delaware 001-38720 46-205888 (State or other jurisdiction of incorporation) (Co |
|
| February 6, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 6, 2020 Twist Bioscience Corporation (Exact name of registrant as specified in its charter) Delaware 001-38720 46-205888 (State or other jurisdiction of incorporation) (Co |
|
| February 6, 2020 |
Twist Bioscience Announces Settlement Agreement with Agilent EX-99.1 Exhibit 99.1 Twist Bioscience Announces Settlement Agreement with Agilent SAN FRANCISCO, Calif. – February 6, 2020 – Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced it has reached a settlement agreement with Agilent Technologies to resolve all claims and count |
|
| January 29, 2020 |
Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Twist Bioscience Corporation (Name of Issuer) Common Stock (Title of Class of Securities) 90184D100 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursu |
|
| January 27, 2020 |
Financial Statements and Exhibits, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 27, 2020 Twist Bioscience Corporation (Exact name of registrant as specified in its charter) Delaware 001-38720 46-205888 (State or other jurisdiction of incorporation) (Co |
|
| January 27, 2020 |
Twist Bioscience Announces Completion of $50 Million Registered Direct Offering Priced At-The-Market EX-99.1 Exhibit 99.1 Twist Bioscience Announces Completion of $50 Million Registered Direct Offering Priced At-The-Market SAN FRANCISCO, Calif. – January 27, 2020 – Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it has issued approximately 2.24 million shares of |
|
| January 13, 2020 |
EX-99.1 Exhibit 99.1 Twist Bioscience Promotes Patrick Weiss to Chief Operating Officer Setting Stage for Future Growth — Bill Banyai, Ph.D., to Lead DNA Data Storage and Technology Development — SAN FRANCISCO, Calif. – January 13, 2020 – Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platfor |
|
| January 13, 2020 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 13, 2020 (January 7, 2020) Twist Bioscience Corporation (Exact name of registrant as specified in its charter) Delaware 001-38720 46-205888 (State or other jurisdiction of |
|
| January 8, 2020 |
TWST / Twist Bioscience Corp DEF 14A - - DEF 14A TABLE OF CONTENTS SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☑ Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☑ Definitive Proxy Statement o Definitive Additional Materials o Soliciting Material Pursuant to § 240. |
|
| January 8, 2020 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 3, 2020 Twist Bioscience Corporation (Exact name of registrant as specified in its charter) Delaware 001-38720 46-205888 (State or other jurisdiction of incorporation) |
|
| December 18, 2019 |
$50,000,000 Twist Bioscience Corporation Common Stock 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-234538 PROSPECTUS SUPPLEMENT (To the Prospectus dated November 6, 2019) $50,000,000 Twist Bioscience Corporation Common Stock We have entered into a sales agreement with Cowen and Company, LLC, or Cowen, dated December 18, 2019, relating to the sale of shares of our common stock offered by this prospectus supplement. In |
|
| December 18, 2019 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 18, 2019 Twist Bioscience Corporation (Exact name of registrant as specified in its charter) Delaware 001-38720 46-205888 (State or other jurisdiction of incorporation) (C |
|
| December 18, 2019 |
EX-1.1 Exhibit 1.1 Execution Version TWIST BIOSCIENCE CORPORATION $50,000,000 COMMON STOCK SALES AGREEMENT December 18, 2019 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: Twist Bioscience Corporation, a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows: 1. Issuance and Sale of Sha |
|
| December 13, 2019 |
TWST / Twist Bioscience Corp S-3/A - - S-3/A S-3/A 1 d795368ds3a.htm S-3/A As filed with the Securities and Exchange Commission on December 13, 2019 Registration No. 333-234538 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Twist Bioscience Corporation (Exact name of registrant as specified in its charter) Delaware 46-2058888 (State o |
|
| December 13, 2019 |
10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| December 13, 2019 |
List of subsidiaries of the Registrant. EX-21.1 Exhibit 21.1 Twist Bioscience Corporation Subsidiaries Twist Bioscience Corporation has the following subsidiaries: 1. Twist Bioscience Worldwide, a Cayman Islands exempted company. 2. Genome Compiler Corporation, a Delaware corporation, which itself owns Twist Bioscience Israel Ltd. (formerly “Genome Compiler Israel Ltd.”), an Israeli company. 3. Twist Bio Computing, LLC, a Delaware limit |
|
| December 12, 2019 |
TWST / Twist Bioscience Corp CORRESP - - CORRESP TWIST BIOSCIENCE CORPORATION 681 Gateway Blvd. South San Francisco, CA 94080 December 12, 2019 VIA EDGAR U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attn: Chris Edwards, Office of Life Sciences Irene Paik, Office of Life Sciences Re: Twist Bioscience Corporation Acceleration Request Acceleration Request Requested Date: December 13, 2019 Requested Time: |
|
| December 11, 2019 |
EX-99.1 Exhibit 99.1 Twist Bioscience Reports Fourth Quarter and Full Year Fiscal 2019 Financial Results — Fiscal 2019 Revenues Increase 114% over Fiscal 2018 to $54.4M- — Continued Strength in Synthetic Biology and NGS Businesses – — Expect FY 2020 Revenues of $80M to $84M – SOUTH SAN FRANCISCO, Calif. – December 11, 2019 – Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers |
|
| December 11, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 11, 2019 Twist Bioscience Corporation (Exact name of registrant as specified in its charter) Delaware 001-38720 46-205888 (State or other jurisdiction of incorporation) (C |
|
| November 20, 2019 |
TWST / Twist Bioscience Corp CORRESP - - CORRESP November 20, 2019 VIA EDGAR AND HAND DELIVERY Orrick, Herrington & Sutcliffe LLP The Orrick Building 405 Howard Street San Francisco, CA 94105-2669 +1 415 773 5700 orrick. |
|
| November 6, 2019 |
Power of Attorney (previously included on signature page) S-3 Table of Contents As filed with the Securities and Exchange Commission on November 6, 2019 Registration No. |
|
| November 6, 2019 |
EX-4.5 Exhibit 4.5 TWIST BIOSCIENCE CORPORATION as the Company and [•], as Trustee Senior Indenture Dated as of [•] TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.01. Definitions 1 Section 1.02. Other Definitions 5 Section 1.03. Incorporation by Reference of Trust Indenture Act 5 Section 1.04. Rules of Construction 6 ARTICLE 2 THE SECURITIES 6 Section 2.01. |
|
| November 6, 2019 |
Form of Subordinated Indenture EX-4.6 Exhibit 4.6 TWIST BIOSCIENCE CORPORATION as the Company and [●], as Trustee Subordinate Indenture Dated as of [●] TABLE OF CONTENTS Clause Page ARTICLE 1 DEFINITIONS AND INCORPORATION BY REFERENCE 2 Section 1.01. Definitions 2 Section 1.02. Other Definitions 7 Section 1.03. Incorporation by Reference of Trust Indenture Act 8 Section 1.04. Rules of Construction 8 ARTICLE 2 THE SECURITIES 8 S |
|
| October 29, 2019 |
8-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 20, 2019 Twist Bioscience Corporation (Exact name of registrant as specified in its charter) Delaware 001-38720 46-205888 (State or other jurisdiction of incorporation) (Co |
|
| October 25, 2019 |
EX-99.1 Exhibit 99.1 Twist Bioscience Appoints Seasoned Life Sciences Industry Executive Nicolas M. Barthelemy to Board of Directors SAN FRANCISCO, Calif. October 25, 2019 Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the appointment of Nicolas M. Barthelemy to |
|
| October 25, 2019 |
8-K 1 d811246d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 24, 2019 Twist Bioscience Corporation (Exact name of registrant as specified in its charter) Delaware 001-38720 46-205888 (State or other jurisdic |
|
| August 9, 2019 |
TWST / Twist Bioscience Corp 10-Q - Quarterly Report - 10-Q 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 1, 2019 |
8-K 1 d763979d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 1, 2019 Twist Bioscience Corporation (Exact name of registrant as specified in its charter) Delaware 001-38720 46-205888 (State or other jurisdiction of |
|
| August 1, 2019 |
EX-99.1 Exhibit 99.1 Twist Bioscience Reports Third Quarter Fiscal 2019 Financial Results and Highlights Commercial and Operational Progress — Revenues Increase 108% over Third Quarter 2018 — — Increasing Fiscal 2019 Revenue Guidance to $52 to $53 Million; Adjusting Net Loss Guidance to $102 to $104 Million to Reflect Acceleration of Commercial Organization — — Continued Strength in Synthetic Biol |
|
| July 24, 2019 |
Submission of Matters to a Vote of Security Holders 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 23, 2019 Twist Bioscience Corporation (Exact name of registrant as specified in its charter) Delaware 001-38720 46-205888 (State or other jurisdiction of (Commission File Numb |
|
| June 14, 2019 |
TWST / Twist Bioscience Corp DEF 14A - - DEF 14A TABLE OF CONTENTS SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☑ Definitive Proxy Statement o Definitive Additional Materials o Soliciting Material Pursuant to § 240. |
|
| May 23, 2019 |
Senior Business Advisor Agreement dated November 1, 2017. EX-10.1 Exhibit 10.1 TWIST BIOSCIENCE CORPORATION SENIOR BUSINESS ADVISOR AGREEMENT This Senior Business Advisor Agreement (the Agreement) is entered into as of November 1, 2017 (the Effective Date), by and between Twist Bioscience Corporation, a Delaware corporation (the Company), and Nelson C. Chan (Advisor). In consideration of the mutual covenants contained herein and other good and va |
|
| May 23, 2019 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 20, 2019 Twist Bioscience Corporation (Exact name of registrant as specified in its charter) Delaware 001-38720 46-205888 (State or other jurisdiction of incorporation) (Commis |
|
| May 23, 2019 |
EX-99.1 Exhibit 99.1 Twist Bioscience Strengthens Board with Semiconductor and Storage Expert Nelson C. Chan Replaces Paul Conley on Board of Directors SAN FRANCISCO, Calif. – May 23, 2019 – Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced it appointed Nelson C. Chan, |
|
| May 9, 2019 |
TWST / Twist Bioscience Corp S-1MEF S-1MEF S-1MEF As filed with the Securities and Exchange Commission on May 8, 2019 Registration No. |
